# US 2013/0252987 A1 · Method of regulating plasma lipoproteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252987 A1
- Document ID: US20130252987A1
- Status: Published application
- Kind: A1
- Application number: 13/876,120
- Filed: 2011-10-12
- Published: 2013-09-26
- Earliest claimed: 2010-10-12
- Assignees: McMaster University
- Inventors: Shirya Rashid
- Web page: https://patentgrep.com/patent/US20130252987A1

## CPC

- C12N 5/0602: {Vertebrate cells}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Y 304/21061: Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
- C12N 2310/14: interfering nucleic acids [NA]
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES

## Abstract

A method of modulating the level of lipoproteins in human cells comprising the step of inhibiting resistin in the cells or cellular environment. The method is useful to treat cardiovascular disease.

## Claims

### Claim 1

A method of modulating the level of lipoproteins in human cells comprising the step of inhibiting resistin within the cellular environment.

### Claim 2 (depends on 1)

The method of claim 1, wherein resistin expression is inhibited.

### Claim 3 (depends on 1)

The method of claim 1, wherein resistin activity is inhibited.

### Claim 4 (depends on 1)

The method of claim 1, wherein the lipoproteins are selected from the group consisting of very low density lipoproteins (VLDL), low density lipoproteins (LDL), intermediate-density lipoproteins (IDL), apolipoproteins, cholesterol and triglycerides.

### Claim 5 (depends on 1)

The method of claim 1, wherein resistin is inhibited to achieve a lipoprotein level that is typical of human subject having a body mass index (BMI) of less than or equal to about 25 kg/m2.

### Claim 6 (depends on 1)

The method of claim 1, wherein resistin is inhibited immunologically.

### Claim 7 (depends on 1)

The method of claim 1, wherein resistin is inhibited by a polynucleotide derived from SEQ ID NO: 1.

### Claim 8 (depends on 7)

The method of claim 7, wherein the polynucleotide is siRNA.

### Claim 9 (depends on 1)

The method of claim 1 to treat a pathological condition in a human subject that results from increased serum levels of undesirable lipoproteins.

### Claim 10 (depends on 9)

The method of claim 9, wherein the pathological condition is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, myocardial infarction, stroke, venous thromboembolism, arterial thromboembolism, obesity, ischemia, stenosis, angina, diabetes and glucose dysregulation.

### Claim 11 (depends on 9)

The method of claim 9, wherein the subject has a level of at least about 90 mg/dL of serum apoB, 150 mg/dL of serum triglycerides, 130 mg/dL of LDL cholesterol or 180 mg/dL of serum cholesterol.

### Claim 12 (depends on 9)

The method of claim 9, including the step of administering to the subject a statin.

### Claim 13

A method of screening candidate resistin inhibiting compounds comprising the steps of:
a) incubating a candidate compound with resistin-expressing sample; and
b) measuring the activity of resistin in the sample, wherein a reduction in the activity of resistin in the sample in comparison to a control value obtained in the absence of incubation with the candidate indicates that the candidate compound is a resistin inhibitor.

### Claim 14 (depends on 13)

The method of claim 13, wherein resistin activity is determined by measuring the level of resistin mRNA, resistin, LDL receptor, PCSK9, VLDL, LDL, apolipoprotein, cholesterol or triglycerides.

### Claim 15

A method of diagnosing elevated lipoprotein levels in a human subject comprising the step of determining in a resistin-expressing sample obtained from the subject the level or activity of resistin, PCSK9 or MTP, wherein an increase in the level or activity of resistin, PCSK9 or MTP in comparison to a control level is indicative of elevated lipoprotein levels.

### Claim 16 (depends on 15)

The method of claim 15, wherein the level or activity of PCSK9 is determined.

### Claim 17 (depends on 15)

The method of claim 15, wherein the level or activity of MTP is determined.
